Recent studies have demonstrated that galectin-3 levels are significantly associated with the diagnosis and prognosis of DBCM patients, as elevated levels correlate with impaired cardiac function, reduced absolute GLS, and an increased risk of cardiovascular events and mortality in individuals with T2DM and reduced LVEF [35,36,37]. This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.